



## Synlogic Reports Second Quarter 2020 Financial Results and Provides Business Update

August 6, 2020

**- Synlogic ends 2Q2020 with \$109.1 million in cash, cash equivalents and investments supporting projected runway into 2022 -**

**- Company continues to advance multiple clinical stage Synthetic Biotic medicines -**

**- Management to host conference call and webcast at 8:00 am ET today -**

CAMBRIDGE, Mass., Aug. 6, 2020 /PRNewswire/ -- Synlogic, Inc. ([Nasdaq: SYBX](#)), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the second quarter ended June 30, 2020, and provided an update on programs and progress.

"Our team at Synlogic continues to achieve our clinical programs and platform milestones, driving the advancement of our portfolio of novel Synthetic Biotic medicines," said Aoife Brennan, M.B. Ch.B., Synlogic's president and chief executive officer. "We are on track to initiate the Phase 2 study of SYNB1618 in Phenylketonuria and the monotherapy arm of our Phase 1 trial of SYNB1891 in solid tumors continues to progress as planned. With the advancement of our pipeline and a cash runway into 2022, we are well positioned to meet our objectives and bring these novel Synthetic Biotic medicines to patients."

"We have rapidly advanced SYNB8802 in Enteric Hyperoxaluria, which leads to dangerously high levels of urinary oxalate and for which patients have few treatment options today," said Richard Riese, M.D., Synlogic's chief medical officer. "We look forward to an IND filing and moving SYNB8802 into the clinic in early 2021."

### 2020 Priorities & Highlights

- **Initiation of a Phase 2 clinical trial to evaluate SYNB1618 in patients with phenylketonuria (PKU).** SYNB1618 is an orally administered Synthetic Biotic medicine being developed as a potential treatment for PKU.
  - Synlogic expects to initiate the Phase 2 clinical trial of SYNB1618 in the second half of 2020, per plan.
  - The Phase 2 trial is designed to evaluate safety and tolerability of a solid formulation of SYNB1618 as well as its potential to lower blood phenylalanine levels in PKU patients.
  - In addition, the study is expected to provide valuable information to validate predictive pharmacodynamic and preclinical modeling.
- **Continuation of the monotherapy arm of the Phase 1 clinical study of SYNB1891 in patients with advanced solid tumors or lymphoma.** SYNB1891 is currently in Phase 1 clinical development in patients with advanced solid tumors or lymphoma.
  - Enrollment in the Phase 1 trial continues per plan
  - Synlogic expects to share data from the monotherapy arm of the Phase 1 clinical study before the end of the year
- **Advancement of SYNB8802 for the treatment of enteric hyperoxaluria**
  - Synlogic is developing SYNB8802 to treat enteric hyperoxaluria. SYNB8802 has moved into IND-enabling studies.
  - Enteric hyperoxaluria is an acquired metabolic disorder in which patients develop recurrent kidney stones due to elevated urinary oxalate levels and are at an increased risk of kidney failure.
- **Synlogic regains all rights to develop Synthetic Biotic medicines for all effectors targeting IBD**
  - On May 21, Synlogic announced the termination of its collaboration with AbbVie.
  - Upon termination, Synlogic regained all rights to develop IBD Synthetic Biotic medicines for all effectors targeting IBD. This allows Synlogic to fully leverage its expertise in strain engineering, quantitative biology, regulatory, and manufacturing to expand its wholly owned GI-based program portfolio to include IBD.
  - Synlogic further regains the rights to partner its IBD programs.
- **First virtual R&D event**
  - On May 27, Synlogic's Executive Team presented an in-depth review of our Synthetic Biotic medicines platform and programs for the treatment of metabolic diseases, inflammatory and immune disorders, and cancer. The team was joined by guest speaker David S. Goldfarb, Professor of Medicine and Physiology and Clinical Chief, Division of Nephrology at NYU School of Medicine; Chief, Nephrology at NY Harbor VA Medical Center, for an overview of

enteric hyperoxaluria.

- The R&D event materials and replay can be found in the Presentations & Publications section of the Synlogic website

- **Synlogic expands Leadership Team and announces senior management promotions**

- Synlogic promoted Antoine (Tony) Awad to the position of Chief Operating Officer.
- Tony joined Synlogic in December 2018 as Head of Technical Operations. He brings over 15 years of experience in the biotechnology and pharmaceutical industry with substantial experience in the development and manufacturing of novel therapeutics from pre-IND studies through global commercialization. Prior to joining Synlogic, Tony served as Senior Vice President of CMC and Operations at Abpro Therapeutics and L.E.A.F. Pharmaceuticals and served in roles of increasing responsibility at Ipsen Biosciences and Merrimack Pharmaceuticals. Tony is a graduate of Boston University and holds degree in biochemistry and molecular biology, and conducted graduate research at Boston University School of Dental Medicine.
- Synlogic also announced the appointment of Andrew Marsh as Head of Clinical Operations.
- Andrew brings over 15 years of experience across an array of therapeutic areas, including rare diseases and oncology, and has executed initial IND through registrational human clinical studies. Prior to joining Synlogic he served as Ra Pharmaceuticals' Head of Clinical Development. Andrew is a graduate of Boston University and holds a degree in biomedical engineering. He will be responsible for Clinical Operations, Biometrics, and Clinical Bioanalytics.

#### **Second Quarter 2020 Financial Results**

As of June 30, 2020, Synlogic had cash, cash equivalents, and short-term investments of \$109.1 million.

For the three months ended June 30, 2020, Synlogic reported a consolidated net loss of \$15.5 million, or \$0.44 per share, compared to a consolidated net loss of \$12.3 million, or \$0.45 per share, for the corresponding period in 2019.

Research and development expenses were \$12.9 million for the three months ended June 30, 2020 compared to \$9.7 million for the corresponding period in 2019.

General and administrative expenses for the three months ended June 30, 2020 were \$3.5 million compared to \$3.7 million for the corresponding period in 2019.

Revenues were \$0.4 million for both the three months ended June 30, 2020 and June 30, 2019, respectively. Revenue for both periods was associated with Synlogic's prior collaboration with AbbVie to develop Synthetic Biotic medicines for the treatment of irritable bowel disease.

#### **Financial Outlook**

Based upon its current operating plan, Synlogic expects to have a projected cash runway into 2022.

#### **Conference Call & Webcast Information**

Synlogic will host a conference call and live webcast today at 8:00 a.m. ET today, Thursday, 6 August 2020. To access the live webcast, please visit the "[Event Calendar](#)" page within the [Investors and Media](#) section of the Synlogic website.

Alternatively, investors may listen to the call by dialing +1 (844) 815-2882 from locations in the United States or +1 (213) 660-0926 from outside the United States. The conference ID number is 5673797. For those unable to participate in the conference call or webcast, a replay will be available for 30 days on the Investors and Media section of the Synlogic website.

#### **About Synlogic**

Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX). The company is also building a portfolio of partner-able assets in immunology and oncology.

#### **Forward-Looking Statements**

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's platform to develop therapeutics to address a wide range of diseases including: cancer, inborn errors of metabolism, and inflammatory and immune disorders; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; the expected timing of Synlogic's clinical trials and availability of clinical trial data; the timing and progress of our Phase 1 clinical trial of SYNB1891 in patients with advanced solid tumors or lymphoma; and the potential benefits of SYNB1891. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

**Synlogic, Inc.**  
**Condensed Consolidated Statements of Operations**  
(unaudited)

(in thousands, except share and per share data)	For the three months ended		For the six months ended	
	June 30, 2020	June 30, 2019	June 30, 2020	June 30, 2019
Revenue	\$ 445	\$ 350	\$ 545	\$ 688
Operating expenses				
Research and development	12,909	9,703	25,586	20,087
General and administrative	3,473	3,742	7,294	7,393
Total operating expenses	<u>16,382</u>	<u>13,445</u>	<u>32,880</u>	<u>27,480</u>
Loss from operations	(15,937)	(13,095)	(32,335)	(26,792)
Other income, net	402	751	972	1,502
Net loss	<u>\$ (15,535)</u>	<u>\$ (12,344)</u>	<u>\$ (31,363)</u>	<u>\$ (25,290)</u>
Net loss per share - basic and diluted	<u>\$ (0.44)</u>	<u>\$ (0.45)</u>	<u>\$ (0.91)</u>	<u>\$ (0.96)</u>
Weighted-average common shares used in computing net loss per share - basic and diluted	<u>34,967,761</u>	<u>27,242,514</u>	<u>34,604,738</u>	<u>26,284,262</u>

**Synlogic, Inc.**  
**Condensed Consolidated Balance Sheets**  
(unaudited)

(in thousands, except share data)	June 30, 2020	December 31, 2019
<b>Assets</b>		
Cash, cash equivalents, and short and long-term investments	\$ 109,136	\$ 127,073
Fixed assets	\$ 12,055	\$ 13,021
Other assets	\$ 38,202	\$ 48,480
Total assets	<u>\$ 159,393</u>	<u>\$ 188,574</u>
<b>Liabilities and stockholders' equity</b>		
Current liabilities	\$ 6,058	\$ 8,863
Long-term liabilities	\$ 21,663	\$ 22,806
Total liabilities	<u>27,721</u>	<u>31,669</u>
Total stockholders' equity	\$ 131,672	\$ 156,905
Total liabilities and stockholders' equity	<u>\$ 159,393</u>	<u>\$ 188,574</u>
Common stock and common stock equivalents		
Common stock	34,145,111	32,266,814
Common stock warrants (pre-funded)	2,548,117	2,548,117
Total common stock	<u>36,693,228</u>	<u>34,814,931</u>

**C** View original content:<http://www.prnewswire.com/news-releases/synlogic-reports-second-quarter-2020-financial-results-and-provides-business-update-301107181.html>

SOURCE Synlogic, Inc.

Media Contact: Caroline Rufo, Ph.D., MacDougall, Phone: 781-235-3060 Email: [crufo@macbiocom.com](mailto:crufo@macbiocom.com) Investor Contact: Daniel Rosan, Synlogic, Inc., Phone: (617) 401-9975, Email: [dan.rosan@synlogictx.com](mailto:dan.rosan@synlogictx.com)